Literature DB >> 9357611

Decision-analytic valuation of clinical information systems: application to an alerting system for coronary angiography.

D S Bell1.   

Abstract

BACKGROUND: Many patients who need coronary angiography fail to get it and they have decreased survival as a result. This study demonstrates the use of decision analysis to predict the survival value of an alerting system for necessary angiography.
METHODS: Data on the use of angiography and survival after myocardial infarction (MI) were taken from a published cohort study. The expected value of information (EVI) was calculated for alerts that angiography is necessary. Maximal EVI was estimated by assuming that alert advice is always followed. Sensitivity analysis relaxed that assumption. Hypothetical data were generated to demonstrate EVI analysis for narrower subcohorts.
RESULTS: A maximally effective alerting system would increase survival in this cohort by 2.2% over 1-4 years after MI. The system would therefore need to be applied to 46 people to prevent one death. Its effectiveness would decrease linearly with decreasing adherence to its advice. Given sufficiently detailed outcome and prevalence data, EVI analysis could also predict the survival value of the system's individual data elements.
CONCLUSIONS: An alerting system that ensures necessary angiography post-MI should have a survival value comparable to the value of t-PA over streptokinase. EVI analysis provides a framework for predicting the overall effectiveness of information systems and for understanding the contribution of individual features to a system's effectiveness.

Entities:  

Mesh:

Year:  1997        PMID: 9357611      PMCID: PMC2233285     

Source DB:  PubMed          Journal:  Proc AMIA Annu Fall Symp        ISSN: 1091-8280


  12 in total

1.  A method for the detailed assessment of the appropriateness of medical technologies.

Authors:  R H Brook; M R Chassin; A Fink; D H Solomon; J Kosecoff; R E Park
Journal:  Int J Technol Assess Health Care       Date:  1986       Impact factor: 2.188

Review 2.  Recommendations of the Panel on Cost-effectiveness in Health and Medicine.

Authors:  M C Weinstein; J E Siegel; M R Gold; M S Kamlet; L B Russell
Journal:  JAMA       Date:  1996-10-16       Impact factor: 56.272

3.  Should clinical trials with concurrent economic analyses be blinded?

Authors:  N Freemantle; M Drummond
Journal:  JAMA       Date:  1997-01-01       Impact factor: 56.272

4.  Focusing technology assessment using medical decision theory.

Authors:  C E Phelps; A I Mushlin
Journal:  Med Decis Making       Date:  1988 Oct-Dec       Impact factor: 2.583

5.  An assessment of clinically useful measures of the consequences of treatment.

Authors:  A Laupacis; D L Sackett; R S Roberts
Journal:  N Engl J Med       Date:  1988-06-30       Impact factor: 91.245

6.  Sequential diagnosis by computer.

Authors:  G A Gorry; G O Barnett
Journal:  JAMA       Date:  1968-09-16       Impact factor: 56.272

Review 7.  Decision analysis.

Authors:  S G Pauker; J P Kassirer
Journal:  N Engl J Med       Date:  1987-01-29       Impact factor: 91.245

8.  Translation of appropriateness criteria into practice guidelines: application of decision table techniques to the RAND criteria for coronary artery bypass graft.

Authors:  R N Shiffman; L L Leape; R A Greenes
Journal:  Proc Annu Symp Comput Appl Med Care       Date:  1993

9.  Variation among hospitals in coronary-angiography practices and outcomes after myocardial infarction in a large health maintenance organization.

Authors:  J V Selby; B H Fireman; R J Lundstrom; B E Swain; A F Truman; C C Wong; E S Froelicher; H V Barron; M A Hlatky
Journal:  N Engl J Med       Date:  1996-12-19       Impact factor: 91.245

10.  Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction.

Authors:  D B Mark; M A Hlatky; R M Califf; C D Naylor; K L Lee; P W Armstrong; G Barbash; H White; M L Simoons; C L Nelson
Journal:  N Engl J Med       Date:  1995-05-25       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.